These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37155024)

  • 1. Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies.
    Tan X; Cai Z; Chen G; Cai C; Chen J; Liang Y; Zhuo Y; Liu J; Huang L; Ouyang B; Wei Y; Jia Z; Deng J; Zhong W; Lu J
    Discov Oncol; 2023 May; 14(1):62. PubMed ID: 37155024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA modification Regulators' Co-Expression Score (RMRCoeS) predicts biochemical recurrence and therapy response in prostate cancer: A multi-omics and experimental validation study.
    Cai Z; Jiang Z; Li S; Mo S; Wang S; Liang M; Tan X; Zhong W; Zhang L; Deng J; Zhong C; Lu J
    Int Immunopharmacol; 2024 Sep; 139():112723. PubMed ID: 39053228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Methylcytosine RNA Methyltransferases-Related Long Non-coding RNA to Develop and Validate Biochemical Recurrence Signature in Prostate Cancer.
    Wang K; Zhong W; Long Z; Guo Y; Zhong C; Yang T; Wang S; Lai H; Lu J; Zheng P; Mao X
    Front Mol Biosci; 2021; 8():775304. PubMed ID: 34926580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
    Xu Z; Chen S; Zhang Y; Liu R; Chen M
    Front Immunol; 2022; 13():869759. PubMed ID: 35603206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Ma Y; Yang J; Ji T; Wen F
    Front Genet; 2022; 13():990623. PubMed ID: 36246622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer.
    Yun D; Yang Z; Zhang S; Yang H; Liu D; Grützmann R; Pilarsky C; Britzen-Laurent N
    Front Cell Dev Biol; 2022; 10():975684. PubMed ID: 36060802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-omic analyses of m5C readers reveal their characteristics and immunotherapeutic proficiency.
    Xu R; Wang Y; Kuang Y
    Sci Rep; 2024 Jan; 14(1):1651. PubMed ID: 38238581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-methylcytosine RNA methylation regulators affect prognosis and tumor microenvironment in lung adenocarcinoma.
    Liu T; Hu X; Lin C; Shi X; He Y; Zhang J; Cai K
    Ann Transl Med; 2022 Mar; 10(5):259. PubMed ID: 35402591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel 5-methylcytosine-related signature for prognostic prediction of kidney renal papillary cell carcinoma and a Putative target for drug repurposing.
    Zhang Z; Cao C; Zhou CL; Li X; Miao C; Shen L; Singla RK; Lu X
    Transl Oncol; 2023 Oct; 36():101741. PubMed ID: 37523897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel m6A/m5C/m1A score signature to evaluate prognosis and its immunotherapy value in colon cancer patients.
    Liu J; Dou M; Liu X; Lu Y; Lu W
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11995-12012. PubMed ID: 37421455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer.
    Lu J; Chen J; Lin Z; Liu Q; Zhong C; Cai Z; Jia Z; Zhong W; Liang Y; Cai C
    Transl Oncol; 2023 Jul; 33():101670. PubMed ID: 37060728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing an m5C regulator-mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer.
    Zhang R; Gan W; Zong J; Hou Y; Zhou M; Yan Z; Li T; Lv S; Zeng Z; Wang W; Zhang F; Yang M
    Front Immunol; 2023; 14():1054700. PubMed ID: 36911744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALYREF-mediated RNA 5-Methylcytosine modification Promotes Hepatocellular Carcinoma Progression Via Stabilizing EGFR mRNA and pSTAT3 activation.
    Nulali J; Zhang K; Long M; Wan Y; Liu Y; Zhang Q; Yang L; Hao J; Yang L; Song H
    Int J Biol Sci; 2024; 20(1):331-346. PubMed ID: 38164181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.
    Yu G; Bao J; Zhan M; Wang J; Li X; Gu X; Song S; Yang Q; Liu Y; Wang Z; Xu B
    Front Immunol; 2022; 13():914577. PubMed ID: 35757739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. m5C regulator-mediated modification patterns and tumor microenvironment infiltration characterization in colorectal cancer: One step closer to precision medicine.
    Chen B; Xi Y; Zhao J; Hong Y; Tian S; Zhai X; Chen Q; Ren X; Fan L; Xie X; Jiang C
    Front Immunol; 2022; 13():1049435. PubMed ID: 36532062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. m5C regulator-mediated methylation modification phenotypes characterized by distinct tumor microenvironment immune heterogenicity in colorectal cancer.
    Chen Z; Li Q; Lin Y; Lin S; Gao J; Chen S
    Sci Rep; 2023 Jul; 13(1):11950. PubMed ID: 37488178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Novel Gene Signature for Predicting the Prognosis by Identifying m5C Modification Subtypes of Cervical Cancer.
    Yu J; Liang LL; Liu J; Liu TT; Li J; Xiu L; Zeng J; Wang TT; Wang D; Liang LJ; Xie DW; Chen DX; An JS; Wu LY
    Front Genet; 2021; 12():733715. PubMed ID: 34630524
    [No Abstract]   [Full Text] [Related]  

  • 18. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
    Zheng P; Li N; Zhan X
    Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.
    Zheng K; Hai Y; Xi Y; Zhang Y; Liu Z; Chen W; Hu X; Zou X; Hao J
    J Transl Med; 2023 Nov; 21(1):789. PubMed ID: 37936202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the expression and prognostic significance of m
    Xu G; Li C; Di Z; Yang Y; Liang L; Yuan Q; Yang Q; Dong X; Xu S; Wu G
    Cancer Med; 2023 Mar; 12(6):7667-7681. PubMed ID: 36464884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.